期刊文献+

左西孟旦联合托伐普坦治疗急性心力衰竭的疗效观察 被引量:16

下载PDF
导出
摘要 目的观察左西孟旦联合托伐普坦治疗急性心力衰竭的疗效。方法 82例急性失代偿性心力衰竭患者,随机分为两组:观察组以左西孟旦联合托伐普坦,对照组只用左西孟旦,分别在治疗前、治疗后7天测量患者心率、收缩压、射血分数(EF)、24小时尿量,比较观察其水平变化。结果两组患者入院时心率、收缩压、EF、24小时尿量比较,差异无统计学意义(均P>0.05)。治疗后以上四项指标均明显改善(P<0.05)。与对照组比较,观察组明显降低患者心率(P<0.05)、收缩压(P<0.01),增加24小时尿量(P<0.01),提高EF值(P<0.01)。两组比较有统计学差异(P<0.05)。结论两种方法均能明显改善急性心力衰竭患者心功能,与对照组比较,左西孟旦联合托伐普坦治疗急性心力衰竭疗效更加显著。
出处 《心脑血管病防治》 2016年第6期465-466,468,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
基金 吴阶平医学基金临床科研项目(编号:320.6750.15159)
  • 相关文献

参考文献3

二级参考文献44

  • 1Dec GW. Acute decompensated heart failure: the shrinking role of inotropic therapy[J]. J Am Coll Cardiol, 2005, 46(1):65.
  • 2Endon M.Mechanisms of action of novel cardiotonic agents [J] .J Cardiovasc Pharmacol, 2002,40 (3) : 323.
  • 3Papp Z, Csapo K, Pollesello P, et al.Pharmacological mechanisms contributing to the clinical efficacy of levosimendan[J]. Cardiov Dse Drug Rev, 2005,23 ( 1 ) : 71.
  • 4Grossini E, Molinari C, Caimmi PP, et al.Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) charmel.[J] BrJPharmacol, 2009 , 156 (2):250.
  • 5Kivikko M, Antila S, Eha J, et al.Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extendedlnfusion in Patients with Severe Heart Failure[J]. J Clin Pharmacol, 2002, 42 (1):43.
  • 6Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study) : a randomised double-blind trial[J]. Lancet, 2002,360 (9 328) : 196.
  • 7Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) [J]. Eur Heart J, 2002, 23 (18):1 422.
  • 8Cleland JG, Ghosh J, Freemantle N, et al.Clinical trials update and cumulative Meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure[J]. Eur J Heart Fail , 2004 , 6 ( 4 ) :501.
  • 9Packer M, Colueci WS, Fisher L, et al.Development of a comprehensive new end point for the evaluation of new treatments for acute decompensated heart failure:results with levosimendan in the REVIVE 1 study[J].J CardFail, 2003,9(5) :61.
  • 10Packer M.REVIVE-2.. Levosimendan improves five-day clinical status in acute HF[R].USA: American Heart Association Scientific Sessions, 2005.

共引文献47

引证文献16

二级引证文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部